Nomura Asset Management CO LTD Iovance Biotherapeutics, Inc. Transaction History

Nomura Asset Management CO LTD

  • $31.8 Billion
  • Q3 2024
Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$7.28 - $11.9 $0 - $0
0 New
0 $0
Q2 2024

Aug 14, 2024
SELL
$7.78 - $14.19 $2.16 Million - $3.95 Million
-278,135 Closed
0 $0
Q1 2024

May 13, 2024
BUY
$7.59 - $17.47 $2.11 Million - $4.86 Million
278,135 New
278,135 $4.12 Million
Q4 2023

Feb 09, 2024
BUY
$3.3 - $8.89 $0 - $0
0 New
0 $0
Q3 2023

Nov 03, 2023
BUY
$4.44 - $8.79 $0 - $0
0 New
0 $0
Q2 2023

Aug 14, 2023
BUY
$5.36 - $9.06 $0 - $0
0 New
0 $0
Q1 2023

May 11, 2023
BUY
$5.53 - $8.22 $0 - $0
0 New
0 $0
Q4 2022

Feb 14, 2023
BUY
$5.62 - $10.0 $0 - $0
0 New
0 $0
Q3 2022

Nov 14, 2022
BUY
$9.53 - $13.11 $0 - $0
0 New
0 $0
Q3 2022

Nov 10, 2022
BUY
$9.53 - $13.11 $0 - $0
0 New
0 $0
Q3 2022

Nov 10, 2022
BUY
$9.53 - $13.11 $0 - $0
0 New
0 $0
Q2 2022

Aug 12, 2022
BUY
$6.38 - $18.33 $0 - $0
0 New
0 $0
Q1 2022

May 13, 2022
BUY
$12.38 - $19.1 $0 - $0
0 New
0 $0
Q4 2021

Feb 01, 2022
BUY
$16.55 - $27.63 $0 - $0
0 New
0 $0
Q3 2021

Nov 12, 2021
BUY
$20.35 - $26.63 $0 - $0
0 New
0 $0
Q2 2021

Aug 06, 2021
BUY
$16.33 - $33.07 $0 - $0
0 New
0 $0
Q1 2021

May 14, 2021
BUY
$28.67 - $52.59 $0 - $0
0 New
0 $0
Q4 2020

Feb 12, 2021
BUY
$28.04 - $50.26 $0 - $0
0 New
0 $0

Others Institutions Holding IOVA

# of Institutions
313
Shares Held
237M
Call Options Held
3.77M
Put Options Held
1.7M
View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

IOVA Quotes by TradingView
  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.16B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Nomura Asset Management CO LTD Portfolio

Follow Nomura Asset Management CO LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Asset Management CO LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email